Welcome to our dedicated page for THERMA BRIGHT ORD news (Ticker: TBRIF), a resource for investors and traders seeking the latest updates and insights on THERMA BRIGHT ORD stock.
Therma Bright Inc. (TBRIF) is a developer and partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies. The company focuses on providing consumers and medical professionals innovative solutions to address today's most important medical challenges. Therma Bright is traded on TSX Venture Exchange (THRM) and OTCQB (TBRIF). Recent achievements include receiving a cease trade order from the Ontario Securities Commission and working diligently to file required documents. Therma Bright also announced the reopening of its application for Venowave device codes and plans for a strategic review to maximize shareholder value.
Rhea-AI Summary
Therma Bright Inc. (TBRIF) will resume trading on the TSXV on February 7, 2024. The company received a letter from the Center of Medicare and Medicaid regarding its Venowave device, confirming the reopening of its application for securing permanent CPT/HCPCS codes. This is a positive development for the company's medical device technologies. Additionally, Therma Bright has received notification from the TSXV about the resumption of stock trading.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.77%
Tags
-
Rhea-AI Summary
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has received a cease trade order from the Ontario Securities Commission for not filing annual financial statements and management's discussion and analysis by the periodic disclosure deadline. The company is working with its new auditor to finalize the documents and aims to file them soon, expecting no lengthy delay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.09%
Tags
-
News
Rhea-AI Summary
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) has announced that its AI-driven Digital Cough Analyzer (DCA) developed in partnership with AI4LYF, is ready for a 513(g) request to the U.S. FDA. The DCA offers advanced features for patients and medical practitioners, aiming to revolutionize remote therapeutic monitoring (RTM) solutions. The technology has the potential to diagnose various health issues through cough data analysis, making it a groundbreaking innovation in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
Rhea-AI Summary
Therma Bright Inc. has opened its distribution channels for its Venowave device, with multiple partners expressing interest in evaluating its commerciality. Pilot units have been shipped to each partner for patient pilot tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
-
Rhea-AI Summary
Therma Bright Inc. appoints Eric Myung as CFO, replacing Victor Hugo. Myung has extensive experience in financial analysis and has worked as CFO for several TSX Venture Exchange companies. The CEO welcomes Myung and Marrelli Support Services to the team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Therma Bright Inc. announces change of auditors from HS & Partners LLP to Zeifmans LLP. Former Auditor terminated and Successor Auditor appointed effective February 22, 2023. Change of auditor approved by board of directors and audit committee. No reservations or reportable events. Appointment of Successor Auditor to be brought before next shareholders' meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Therma Bright Inc. announces amended agreement to acquire 25% interest in InStatin and InVixa, with an option to acquire additional shares. Therma will issue 55,000,000 shares to the Vendors in exchange for shares in InVixa and InStatin. Therma also has the option to purchase more shares in InStatin for up to $499,997.08.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.1%
Tags
-
Rhea-AI Summary
Therma Bright Inc. announces partnership with Hero LifeCare for distribution of Venowave device in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Therma Bright Inc. submits updated FDA 510K application for Venowave device, aiming to secure permanent CPT and HCPCS codes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Therma Bright Inc. receives time extension from CMS to secure permanent code for Venowave device
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
FAQ
What is the current stock price of THERMA BRIGHT ORD (TBRIF)?
The current stock price of THERMA BRIGHT ORD (TBRIF) is $0.01894 as of November 21, 2024.
What is the market cap of THERMA BRIGHT ORD (TBRIF)?
The market cap of THERMA BRIGHT ORD (TBRIF) is approximately 9.5M.
What is Therma Bright Inc.?
Therma Bright Inc. is a developer and partner in proprietary diagnostic and medical device technologies.
Where is Therma Bright Inc. traded?
Therma Bright Inc. is traded on the TSX Venture Exchange (THRM) and OTCQB (TBRIF).
What recent achievements has Therma Bright Inc. made?
Recent achievements include receiving a cease trade order from the Ontario Securities Commission and reopening the application for Venowave device codes.
What strategic initiative is Therma Bright Inc. undertaking?
Therma Bright Inc. is initiating a strategic review process to explore alternatives to maximize shareholder value.
What is the focus of Therma Bright Inc.'s technologies?
Therma Bright Inc. focuses on providing consumers and medical professionals with innovative solutions to address important medical challenges.
THERMA BRIGHT INC ORD